Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.57 USD

38.57
547,082

+0.11 (0.29%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Halozyme Therapeutics, Inc. [HALO]

Reports for Purchase

Showing records 161 - 180 ( 181 total )

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

01/20/2012

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

01/06/2012

Industry Report

Pages: 37

LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

12/06/2011

Company Report

Pages: 6

Positive Phase II Data for Cinryze in Combination With rHuPH20 - Insulin Pump Data Expected Q1:12

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

12/01/2011

Industry Report

Pages: 40

December 2011 Potential Milestones & Key Events - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

11/10/2011

Daily Note

Pages: 6

Expert Call Highlights - HALO''s Hylenex Insulin Pump Opportunity "A Game Changer

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

11/09/2011

Company Report

Pages: 7

Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

10/21/2011

Daily Note

Pages: 4

Positive Phase II Diabetes Data Could Provide Partnership and Upside, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

10/19/2011

Company Report

Pages: 5

Positive Phase III Data for SC Herceptin - Increasing Price Target to $14 from $10 per Share; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

10/04/2011

Industry Report

Pages: 24

Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

06/27/2011

Industry Report

Pages: 5

HIGHLIGHTS FOR JUNE 27, 2011

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

06/27/2011

Daily Note

Pages: 4

Reports Positive Phase I Data for Aspart-PH20 Trial at ADA

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

05/06/2011

Company Report

Pages: 7

Q1:11 Update - Progress Report

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

03/22/2011

Company Report

Pages: 7

No Fallen Angel -Buy Ahead of H2 Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

03/15/2011

Company Report

Pages: 6

Q4:10 Results and Update

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

02/01/2011

Daily Note

Pages: 11

2011 Potential Milestones & Key Events - February Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

10/15/2010

Company Report

Pages: 5

Hosts Analyst Meeting; Clarifies Development Strategy

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

08/09/2010

Company Report

Pages: 9

Reports Q2:10 Earnings

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

06/29/2010

Company Report

Pages: 13

Phase II Study Data Examining Insulin Analogs with and without PH20 Presented at ADA Meeting.

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 50.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

06/23/2010

Industry Report

Pages: 65

Life Sciences: Biopharmaceuticals / Biotechnology.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 150.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

06/15/2010

Company Report

Pages: 12

Review of the PH20/Insulin Program Abstracts To Be Presented at the American Diabetes Association Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party